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Volume 43, Number 2 Abstracts 427Sequential Femoral Distal Composite Bypass with Second Generation
Glutaraldehyde Stabilized Human Umbilical Vein (HUV)
Neufang A, Espinola-Klein C, Dorweiler B, et al. Eur J Vasc Endovasc Surg
2005;30:176-83.
Conclusion: Limb salvage and graft patency rates with sequential
composite bypasses composed of second generation human umbilical vein
grafts and autogenous vein provide reasonable primary and secondary pa-
tency rates and are associated with excellent limb salvage.
Summary: The authors sought to evaluate a policy of using a combi-
nation of second generation human umbilical vein (HUV) grafts and autog-
enous vein as a sequential conduit in patients felt to have inadequate
autogenous conduit for construction of an all autogenous lower extremity
bypass. This was a retrospective study from a single center in Germany.
From January 1998 to December 2003, 1,231 infrainguinal bypasses were
performed in this center. Of those, 54 consisted of a femoral-distal HUV-
autologous vein sequential composite bypass. All patients had critical leg
ischemia and were felt to have an absence of sufficient length of autogenous
vein. The sequential HUV-composite technique was reviewed for graft
patency, limb salvage, and patient survival.
Primary and secondary patency rates at 1, 2, 3 and 4 years were 71, 61,
53 and 53%, and 89, 80, 73 and 67% respectively. Limb salvage rates at 1, 2,
3, and 4 years were 96, 92, 88 and 88%. Four year survival was 56%. After
one month, additional graft based procedures were required in six bypasses.
Five patients had asymptomatic occlusion of one sequential anastomosis.
There were no identified complications related to bio-degeneration of the
HUV graft.
Comment: There still remains some interest in the use of human
umbilical vein grafts. The author’s technique of using human umbilical vein
grafts as the prosthetic component of a prosthetic/autologous sequential
composite bypass has provided reasonable results in terms of both patency
and limb salvage. The results differ little from what one would expect with
similar procedures with PTFE grafts. Bio-degeneration of the HUV grafts in
this series of limb salvage patients appeared to be a non issue. If a sequential
composite autogenous graft is required it appears to make little difference
whether the prosthetic component is PTFE or human umbilical vein.
Immediate and 1-Year Outcome of Percutaneous Intervention of Sa-
phenous Vein Graft Disease with Paclitaxel-Eluting Stents
Tsuchida K, Ong ATL, Aoki J, et al. Am J Cardiol 2005;96:395-8.
Conclusion: Implantation of paclitaxel-eluting stents in stenotic cor-
onary artery bypass saphenous vein grafts is feasible and safe with a low rate
of re-intervention at one year.
Summary: In native coronary arteries drug eluting stents dramatically
reduce restenosis following percutaneous angioplasty. This study reports the
use of paclitaxel-eluting stents in the treatment of stenotic lesions of coro-
nary saphenous vein grafts. Between February and December of 2003, the
authors performed interventions in 50 consecutive patients with 62 coronary
vein graft lesions. Two patients died immediately of cardiogenic shock and
eight patients received bare metal stents due to unavailability of appropri-
ately sized paclitaxel-eluting stents. Overall, there were 40 consecutive
patients with 52 coronary vein graft lesions who were treated electively with
paclitaxel-eluting stents. All patients received a loading dose of 300 mgs of
clopidogrel followed by 75 mgs of clopidogrel per day for six months. They
were subsequently maintained on life long aspirin. In addition, heparin, with
an activated clotting time of greater than 250 seconds, was utilized during
the stent implantation procedure. Thrombectomy devices or glycoprotein
2B/3A inhibitors were used at the discretion of the interventional cardiol-
ogist. Patients were followed and evaluated for survival using Kaplan-Meier
analysis. End points were major adverse cardiac events (MACE) and were
defined as death, myocardial infarction, target lesion revascularization or
target vessel revascularization. During followup, one patient (2.5%) had a
non Q-wave MI as an in-hospital complication. No patient died and the
cumulative MACE rate was 7.5%, with a one year event free survival of rate
of 92.5%.
Comment: It appears coronary vein grafts can be successfully treated
with paclitaxel-eluting stents with associated favorable short term clinical
follow-up. (No angiographic follow-up was presented in this study.) The
different flow characteristics of peripheral saphenous vein grafts versus
coronary grafts are obvious. Therefore, this data cannot be used to justify
treatment of peripheral saphenous vein grafts with drug eluting stents.
However, the results are certainly intriguing and it is only a matter of time
before drug eluting stents will be placed in peripheral vein grafts.Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy,
For Prevention of Vein Graft Failure Following Coronary Artery
Bypass Graft Surgery, Prevent IV: A Randomized Control Trial
Prevent IV Investigators. JAMA 2005;294:2446-54.
Conclusion:The E2F decoy edifoligide does not prevent angiographic
vein graft failure at 12 to 18 months following coronary artery bypass
surgery.
Summary: E2F transcription factors up regulate genes believed to play
a role in intimal hyperplasia. The E2F decoy edifoligide may prevent neointi-
mal hyperplasia and subsequent vein graft failure by inhibiting up regulation of
the E2F transcription factors implicated in neointimal hyperplasia.
This was a Phase 3 randomized, double blind, placebo controlled trial
of patients undergoing first time coronary artery bypass surgery and who had
at least two planned saphenous vein grafts. There were 107 U.S. sites
involved in the study. Vein grafts were treated ex vivo with either placebo or
the E2F decoy. Angiographic followup was at 12-18 months in the first
2,400 patients enrolled in the study. The primary end point was angio-
graphic vein graft stenosis (75%) at 12-18 months following CABG. Also
recorded were adverse events through 30 days and major cardiac adverse
events.
There were 1,920 patients who either died (n  91) or underwent
followup angiography (n  1,829). The primary end point was reached in
436 of 965 patients in the edifoligide group (45.2%) and in 442 of 995
patients in the placebo group (46.3%). (Odds ratio: 0.96 [95% CI, 0.8-
1.14], p  0.66). There was also no effect on any secondary angiographic
end point or major cardiac events at one year (6.7% of 1,508 patients in the
edifoligide group versus 8.1% of 1,506 patients in the placebo group,
Hazard ratio 0.83, 95% CI, 0.64-1.08; p  0.16).
Comment: This study, along with Prevent III, which also failed to
show benefit of edifoligide in preventing vein graft failure for peripheral
arterial reconstructions, provides conclusive evidence as to the ineffective-
ness of edifoligide in preventing neointimal hyperplasia. It is now known,
however, that the E2F family of transcription factors contains at least eight
unique E2F transcription factors. (Journal Biologic Chemistry 2005;280:
18211-20). Some of these transcription factors inhibit neointimal hyperpla-
sia while others appear to promote neointimal hyperplasia. Edifoligide
inhibits the entire E2F family and therefore failure of the apparent “shot-
gun” approach employed in Prevent III and Prevent IV was perhaps inevi-
table. Future research in this area will need to focus on effects of specific E2F
transcription factor decoys.
Nitric Oxide Modulates Vascular Inflammation in Intimal Hyperplasia
and Insulin Resistance in the Metabolic Syndrome
Barbato JE, Zuckerbraun BS, Overhaus, M, et al. Am J Physiol Heart Circ
Physiol 2005;289:H228-36.
Conclusion: Inducible nitric oxide synthase (iNOS) gene transfer can
inhibit the arterial injury response and reduce neointimal formation.
Summary: Both the metabolic syndrome and Type II diabetes mellitus
are characterized by insulin resistance. Both are associated with atheroscle-
rotic vascular disease and may have increased risk of poor outcome following
vascular intervention. The vascular events associated with Type II diabetes
mellitus and the metabolic syndromemay be related to reduced bioavailabil-
ity of nitric oxide (NO) and a heightened inflammatory environment. The
authors sought to characterize the vascular injury response in diabetes and
the metabolic syndrome by studying obese Zucker rats and examining
expression of adhesion molecules, development of intimal hyperplasia, and
recruitment of inflammatory cells. The ability of exogenous NO to inhibit
the vascular injury response in the metabolic syndrome was also studied.
Both lean and obese Zucker rats were subject to a carotid artery balloon
injury model. P-selectin and ICAM-1 expression was increased following
balloon injury in obese animals compared to lean ones. The obese rats had
increased macrophage infiltration of the vascular wall and increased
neointimal formation compared to lean animals (intima/media  0.91 v
0.52, P  0.001). There was a significant reduction in ICAM-1, P-
selectin, inflammatory cell influx and oxidized LDL receptor expression
following adenovirus-mediated inducible NO synthase (iNOS) gene trans-
fer. Proliferative activity was also significantly reduced by iNOS gene transfer
(54% and 73%; P  0.05). Neointimal formation was also reduced in lean
versus obese rats (53% and 67%; P  0.05) with iNOS gene transfer.
Comment: It is known that the vascular injury response and insulin
resistant states are characterized by increased adhesion molecule expression.
The authors gene basedmethod of delivering iNOS appeared to significantly
inhibit adhesion molecule expression. The findings suggest that increasing
NO bioavailability may reduce the augmented inflammatory response and
oxidative stress characteristic of insulin resistance and vascular injury.
